Beta-Lactam Not as Effective as Beta-Lactam Plus Macrolide for Treating CAP in the Hospital
Am Fam Physician. 2015 May 15;91(10):720.
Is a beta-lactam antibiotic alone as effective as the combination of a beta-lactam and a macrolide for treating patients hospitalized with community-acquired pneumonia (CAP)?
In this noninferiority trial, monotherapy with a beta-lactam was not as effective as combination therapy with a beta-lactam and a macrolide for achieving clinical stability in seven days for hospitalized patients with moderately severe CAP. (Level of Evidence = 1b)
Using concealed allocation, these authors randomized 580 hospitalized, immunocompetent patients with CAP to receive monotherapy with a beta-lactam or a beta-lactam in combination with a macrolide. The beta-lactams used were cefuroxime (Zinacef) or amoxicillin/clavulanic acid (Augmentin), and the macrolide used was clarithromycin (Biaxin). Patients with severe pneumonia (for example, those in risk class V on the pneumonia severity index [PSI]) were excluded. The two groups were balanced at baseline: the mean age was 76 years and almost 75% of the patients were PSI class III or IV. The median duration of antibiotic therapy in both groups was 10 days.
The primary outcome was clinical stability at seven days, defined as stable vital signs including an oxygen saturation by pulse oximetry of greater than 90% on room air. Compared with the combination therapy group, a greater proportion of patients in the monotherapy group did not reach clinical stability at seven days (41.2% vs. 33.6%). For the absolute difference between the two groups, the upper limit of the 90% confidence interval was 13%, which exceeded the predefined boundary of a difference of 8% that was required to demonstrate non-inferiority. In other words, monotherapy was not as effective as combination therapy. Additionally, although there were no significant differences in intensive care unit admissions, lengths of stay, or mortality between the two groups, patients in the monotherapy group were more likely to be readmitted within 30 days than were those in the combination group (8% vs. 3%; P = .01). Finally, a subgroup analysis showed that patients with identified atypical pathogens were less likely to reach clinical stability with monotherapy (hazard ratio = 0.33; 95% confidence interval, 0.13 to 0.85).
Study design: Randomized controlled trial (nonblinded)
Funding source: Government
Setting: Inpatient (any location)
Reference: Garin N, Genné D, Carballo S, et al. ß-lactam monotherapy vs. ß-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med.. 2014; 174( 12): 1894– 1901.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP,search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Medical Editor.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Nov 15, 2020
Access the latest issue of American Family Physician